Every 10-Q that BIO-key International, Inc. (BKYI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BKYI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BKYI filings page.
BIO-key International, Inc. reported higher revenue but continued losses for the quarter and six months ended June 30, 2026. Three‑month revenue rose to $1.92 million from $1.70 million, with a net loss of $576,852, an improvement from a $1.17 million loss a year earlier. For the first half of 2026, revenue increased to $4.07 million from $3.30 million, while the net loss narrowed to $781,889 from $1.90 million, aided by a large reversal of previously reserved hardware inventory.
Cash and cash equivalents were $1.38 million and working capital about $0.79 million at June 30, 2026. Management states the company requires roughly $750,000 per month to operate and does not currently have sufficient cash for twelve months of operations, leading to substantial doubt about its ability to continue as a going concern. The company has relied on warrant exercises, secured notes, equity issuances, and receivables factoring to fund operations and continues cost‑cutting and inventory monetization initiatives.
BIO-key International, Inc. reports Q1 2026 results showing higher sales but continued losses and tight liquidity. Revenue rose to $2.15 million, up 33% from $1.61 million a year earlier, driven mainly by stronger license fees and a 125% increase in hardware revenue.
Gross profit increased to $1.77 million, while the net loss narrowed to $205,037 from $736,545. Operating cash outflow improved to $358,001, but cash and equivalents declined to $2.25 million, and management estimates it needs about $750,000 per month to run the business.
The company discloses substantial doubt about its ability to continue as a going concern, noting a history of losses, negative operating cash flow and reliance on new financing or inventory sales. It also highlights Nasdaq notices, a reverse stock split, and that its shares now trade on OTC Markets while it awaits a Nasdaq appeal decision.
BIO-key International, Inc. (BKYI) reported mixed quarterly results with revenue growth but continued losses and a going-concern qualification. For the three months ended June 30, 2025, total revenue was $1,696,907, up from $1,141,286 a year earlier, driven by higher hardware sales and modest license and services growth. Gross profit improved to $1,232,727. The company recorded a net loss of $1,167,396 for the quarter (basic and diluted loss per share $0.20) and a six-month net loss of $1,903,941.
Liquidity changed materially: cash and cash equivalents rose to $2,275,344 from $437,604 at year-end, largely from warrant exercises that generated gross proceeds of approximately $3.8 million and $3,493,505 of net financing cash. Working capital was about $503,000. Management discloses substantial doubt about the company's ability to continue as a going concern without additional financing. Major customer concentration remains (two customers represented 47% of quarterly revenue) and inventory includes a large reserve against finished goods related to delayed projects.